Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell lymphoma.

A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who had blue light vs white light cystoscopy.

The FDA has cleared EVM14, making it the first mRNA therapeutic cancer vaccine for global clinical trials.

For Nutrition Awareness Month, we highlight the importance of tailoring dietary strategies to patients with cancer to improve outcomes and quality of life.

A recent study suggests that using artificial intelligence to measure tumor size could reduce treatment failures by more than 70%.

Positive data and developments to be aware of in AML, breast cancer, PDAC, and NMIBC.

Anita D'Souza, MD, discussed the results from the MajesTEC-2 and TRIMM-2 trials in patients with multiple myeloma.

Investigators found that higher persistent PSA levels after surgery were linked to a worse prognosis, underscoring the importance of timing in post-operative care.

With changes in demographics and advancements in cancer care, the current oncologist workforce is expected to experience an imbalance in supply and demand.

PEP-010 was granted FDA orphan drug designation for the treatment of pancreatic cancer.

Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.

TLX007-CDx is now an FDA-approved PSMA PET imaging agent in prostate cancer.

During a live event, James W. Smithy, MD, MHS, and other oncologists discussed how their experience with immune-related adverse events in metastatic melanoma has developed over time.

The FDA has extended its review of the ProSense cryoablation system for early-stage breast cancer, with a decision expected after the first quarter of 2025.

ST316, a β-catenin/BCL9 antagonist, demonstrated safety, target engagement, and early antitumor activity in advanced solid tumors.

The anti–PD-1/VEGF combination of pembrolizumab and bevacizumab elicited strong clinical activity in patients with melanoma brain metastases.

During a live event, Catherine J. Lee, MD, MS, discussed the efficacy and safety results of various trials of approved agents for treating chronic graft-vs-host disease.

During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant nivolumab in patients with bladder cancer.

The combination of pembrolizumab, trastuzumab, and chemotherapy is now approved in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

The first patient in a trial received oral zelenirstat, a N-myristoyltransferase inhibitor, to determine its safety and tolerability in relapsed/refractory AML.

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line treatment.

Tarlatamab showed a positive benefit-risk profile in small cell lung cancer, per the phase 2 DeLLphi-301 study.

A phase 3 trial plans to evaluate Pro-ocular for the treatment of patients with ocular graft-vs-host disease.

Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib in stage III BRAF-mutated melanoma.

During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma with immunotherapy.